Several therapeutic approaches are currently being developed for Duchenne muscular dystrophy (DMD) including upregulating the levels of endogenous utrophin A in dystrophic fibers. Here, we examined the role of posttranscriptional mechanisms in controlling utrophin A expression in skeletal muscle. We show that activation of p38 leads to an increase in utrophin A independently of a transcriptional induction. Rather, p38 controls the levels of utrophin A mRNA by extending the half-life of transcripts via AU-rich elements (AREs). This mechanism critically depends on a decrease in the functional availability of KSRP, an RNA-binding protein known to promote decay of ARE-containing transcripts. In vitro and in vivo binding studies revealed that KSRP interacts with specific AREs located within the utrophin A 3 ′ UTR. Electroporation experiments to knockdown KSRP led to an increase in utrophin A in wild-type and mdx mouse muscles. In pre-clinical studies, treatment of mdx mice with heparin, an activator of p38, causes a pronounced increase in utrophin A in diaphragm muscle fibers. Together, these studies identify a pathway that culminates in the post-transcriptional regulation of utrophin A through increases in mRNA stability. Furthermore, our results constitute proof-of-principle showing that pharmacological activation of p38 may prove beneficial as a novel therapeutic approach for DMD.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe and prevalent neuromuscular disease that results from mutations/deletions in the X-linked dystrophin gene. These mutations/deletions prevent production of a large cytoskeletal protein of the spectrin superfamily called dystrophin (1, 2) . In normal skeletal muscle, dystrophin accumulates at the cytoplasmic face of the sarcolemma where it interacts with a macromolecular complex of proteins referred to as the dystrophin-associated proteins (DAPs) (3 -6) . Together, this complex of proteins plays a predominant role in maintaining membrane integrity and stability. The lack of dystrophin as seen in DMD muscle fibers makes the sarcolemma highly sensitive to repetitive contractile activity leading to fiber degeneration/regeneration. Over time, the ability of muscle to regenerate its fibers fails, leading to infiltration of adipose and connective tissues within muscle compartments. Several therapeutic approaches are currently being developed to counteract the deleterious effects of this progressive disease including cell and gene therapy (7 -10) .
Over the last two decades, a number of laboratories around the world have focused their efforts on studying the mechanisms regulating expression of utrophin A in skeletal muscle (11) (12) (13) (14) . The rationale for this is that since utrophin A presents a high degree of sequence identity with dystrophin and since it can also associate with members of the DAP (15 -17) , utrophin * To whom correspondence should be addressed at: Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada K1H 8M5. Tel: +1 6135625800/8383; Email: jasmin@uottawa.ca A may therefore represent an ideal surrogate for dystrophin able to compensate functionally for its absence in DMD muscle fibers. In fact, several previous studies have established that increased expression of utrophin A achieved via different means can alleviate the dystrophic pathology and restore membrane function in animal models, thereby providing strong evidence that utrophin A is an excellent substitute to dystrophin (18) (19) (20) . Therefore, deciphering the mechanisms controlling utrophin A expression in skeletal muscle is of great interest in attempts to identify cellular targets and signaling pathways that can be manipulated pharmacologically with drugs and/or small molecules in order to increase endogenous expression of utrophin A in dystrophic muscle fibers (21) (22) (23) (24) .
To date, most of the studies focusing on the molecular events presiding over utrophin A expression in muscle have examined transcriptional regulatory mechanisms (13, (25) (26) (27) . Nonetheless, converging lines of evidence have begun to show that utrophin A is also subject to important post-transcriptional events (28, 29) including translational control (30 -33) . In this context, it is well established that the control of mRNA stability is an important component of regulated gene expression. Work in our laboratory has in fact shown that the stability and targeting of utrophin A transcripts in skeletal muscle cells is regulated by cis-elements contained within the 3 ′ untranslated region (UTR) (28, 29) . In particular, we previously showed the critical role of AU-rich elements (AREs) in the control of utrophin A mRNA stability (28) .
Almost 8% of mammalian-coding mRNAs contain AREs in their 3
′ UTR (34) , making this regulatory site one of the most prevalent cis-acting elements responsible for mRNA decay in cells (35, 36) . To mediate their effects on transcript stability, and hence control mRNA steady-state levels, AREs require interactions with proteins collectively referred to as ARE-binding proteins (AUBPs) (37) (38) (39) . The activity of these proteins in stabilizing or destabilizing target mRNAs is known to be significantly modulated by post-translational modifications including, for example, phosphorylation. Given these facts and our initial observations described above, we set out in the present study to (i) identify signaling cascades that regulate utrophin A expression post-transcriptionally; (ii) characterize AUBPs that are targets of this signaling cascade and determine whether they modulate the stability of pre-synthesized utrophin A transcripts; (iii) define the precise cis-acting elements in the 3 ′ UTR responsible for controlling utrophin A mRNA stability in skeletal muscle and (iv) determine the therapeutic potential of these events in pre-clinical studies using both wild-type and mdx mice. 
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RESULTS

Activation of p38 signaling induces utrophin A expression
The p38 MAPK signaling cascade is well recognized for its importance in skeletal muscle differentiation and growth (40) (41) (42) through its role in controlling both transcriptional and posttranscriptional pathways (43) . To determine whether the activation of p38 signaling regulates utrophin A expression in muscle, we initially stimulated this pathway in C2C12 myoblasts via ectopic expression of MKK6-EE which is an upstream kinase but in this case, mutated to be constitutively active. In these experiments, p38 phosphorylation was significantly increased by 70% (P , 0.01) in C2C12 cells transfected with the active MKK6-EE mutant, whereas total levels of p38 remained unchanged (P . 0.05; Fig. 1A and B). In contrast, substitution of serine 207 and threonine 211 with alanine in MKK6, which results in a dominant-negative kinase called MKK6-AA, completely abrogated phosphorylation of p38 ( Fig. 1A and B) . Next, we examined whether the expression of utrophin A was increased in cells in which p38 signaling was stimulated. Transfection of MKK6-EE in C2C12 myoblasts caused a 2-fold increase (P , 0.01) in utrophin A protein levels (Fig. 1C) . In contrast, ectopic expression of the dominant-negative MKK6-AA failed to increase the expression of utrophin A. To further analyze the potential effects of activating p38, we also determined the levels of utrophin A transcripts. Similar to the increase seen with utrophin A protein, the abundance of utrophin A mRNA was also significantly increased ( 60%; P , 0.05) in cells overexpressing MKK6-EE (Fig. 1D) . Furthermore, utrophin A protein and mRNA levels were significantly decreased (P , 0.05) with the ectopic expression of the dominant-negative MKK6-AA ( Fig. 1C and D) . Taken together, these data indicate that phosphorylation of p38 and hence, activation of this pathway, enhances utrophin A expression in skeletal muscle cells.
Activation of p38 signaling regulates utrophin A expression via a post-transcriptional mechanism
The results presented above indicate that regulation of utrophin A under these conditions is controlled by transcriptional and/or post-transcriptional mechanisms. To assess the potential contribution of transcriptional events, we first conducted experiments using an utrophin A promoter -reporter construct which was co-transfected with MKK6-EE, or pcDNA3 as a control, in C2C12 myoblasts. The utrophin A promoter corresponds to the human 1.3 kb fragment which we (13, 44, 45) and others (11, 12, 14, 46) have studied extensively over the years and shown that it recapitulates in transgenic mice, the pattern of expression of utrophin A mRNA during postnatal muscle development, muscle regeneration as well as within the synaptic compartment of skeletal muscle fibers (47) .
As shown in Figure 2A , activation of p38 signaling did not increase (P . 0.05) expression of the luciferase reporter driven by the utrophin A promoter. Since p38 activation is known to cause * * P , 0.01; * * * P , 0.001; relative MKK6-EE to pcDNA3.1. $$$, P , 0.0001; relative MKK6-EE to MKK6-EE + SB. ( Fig. 2A and B: one-way ANOVA and Bonferroni as Post-hoc test; Fig. 2D ; linear regression and one-way ANOVA and Bonferroni as Post-hoc test).
an increase in the activity of the MyoD and myogenin promoters (48), we also measured their activation, as positive controls, following MKK6-EE overexpression. As expected, we observed significant inductions (P , 0.001) in the activity of both promoters following activation of p38 signaling ( Fig. 2A) . These results suggest, therefore, that transcriptional mechanisms are not involved in the upregulation of utrophin A mRNA and protein following stimulation of the p38 signaling cascade.
Based on these observations, we thus focused on the contribution of post-transcriptional events in the regulation of utrophin A mRNA in myoblasts with activated p38 signaling. As a first approach, we cloned the full-length 3 ′ UTR of the mouse utrophin A transcript and inserted it downstream of the luciferase reporter gene driven by a constitutive promoter. Co-transfection of this 3 ′ UTR-reporter construct with MKK6-EE into C2C12 myoblasts resulted in an 4-fold increase (P , 0.001) in luciferase activity compared with the control (Fig. 2B) . In contrast, luciferase activity remained unchanged (P . 0.05) when the 3 ′ UTR reporter was co-transfected with the dominant-negative MKK6-AA mutant (Fig. 2B ). To complement these experiments, we also directly determined the half-life of utrophin A mRNA in cells overexpressing MKK6-EE. To this end, we activated p38 signaling in C2C12 myoblasts for 24 h, subsequently inhibited transcription by adding actinomycin D (49) , and then measured the relative abundance of utrophin A mRNA at 0, 3, 6 and 9 h thereafter. As shown in Figure 2C and D, the half-life of utrophin A mRNA was significantly increased (P , 0.01) in cells transfected with the constitutively active MKK6-EE mutant (t 1/2 ¼ 14.7 + 2.9 h) in comparison to control (t 1/2 ¼ 6.2 + 0.1 h). In a complementary set of experiments, we determined that the half-life of utrophin A mRNA was similar to control values (P . 0.05) in cells overexpressing MKK6-EE and simultaneously treated with a specific inhibitor of p38 signaling (SB203580). Together with the promoter studies and the 3 ′ UTR-reporter assays, these findings lead us to conclude that phosphorylation and activation of p38 enhance the stability of pre-synthesized utrophin A mRNA via its 3 ′ UTR.
The RNA-binding protein KSRP modulates utrophin A mRNA levels An important question raised by the findings described above concerns the identity of trans-acting factors that can influence the stability of utrophin A mRNA via p38 signaling. In this context, activation of p38 was recently shown to phosphorylate the RNA-binding protein KSRP (for K homology splicing regulator protein), thereby reducing its ability to interact with target transcripts (50, 51) . Functionally, KSRP is well recognized for interacting with ARE-containing mRNAs and promoting their decay by recruiting target transcripts to the degradation machinery (52, 53) . Since utrophin A contains several putative AREs in its 3 ′ UTR, we thus wondered whether KSRP regulates utrophin A mRNA post-transcriptionally.
To determine the functional relevance of KSRP in the control of utrophin A mRNA decay, we first knocked down KSRP using transient transfections of a vector encoding a short-hairpin RNA targeting KSRP. Suppression of KSRP induced a 3-fold increase (P , 0.001) in the levels of utrophin A (Fig. 3A and B) . Importantly, levels of endogenous utrophin A mRNA were also significantly increased (P , 0.001) in C2C12 cells with reduced KSRP when compared with cells transfected with a control vector (Fig. 3C) . For overexpression studies, we resorted to neuroblastoma (N2a) cells because it proved difficult to consistently achieve high levels of KSRP overexpression in C2C12 cells. Using this model system, we were able to confirm the functional regulatory link between utrophin A mRNA and KSRP since we detected an 50% decrease in both utrophin A mRNA (P , 0.001) and protein (P , 0.05) in KSRPoverexpressing cells (Fig. 3D and E) .
We then proceeded to determine whether these effects occurred through alterations in the half-life of utrophin A mRNA. To this end, we measured the half-life of utrophin A transcripts in cells with reduced levels of KSRP and treated with actinomycin D to inhibit transcription. As shown in Figure 3F , knockdown of KSRP levels led to an increase (P , 0.05) in utrophin A mRNA half-life (t 1 The 3 ′ UTR of the mouse utrophin A transcript is 2150 nucleotides in length. We thus performed a bioinformatics analysis using recent software (54) to identify putative AREs (29) . Although six potential AREs were identified, a sequence comparison among human, mouse and rat revealed, however, that only three were conserved across species (Fig. 4A) . Based on this, we hypothesized that the KSRP/3 ′ UTR-dependent repression of utrophin A mRNA expression is mediated by these conserved AREs which correspond to AREs 1, 2 and 4.
Initially, we examined expression of the 3 ′ UTR reporter in cells with reduced (sh-KSRP) or increased (CMV-KSRP) levels of KSRP and found that luciferase activity was markedly affected under these conditions (Fig. 4B ). More specifically, luciferase activity was increased (P , 0.001) in cells with reduced amounts of KSRP, whereas reporter activity was decreased (P , 0.001) in cells overexpressing KSRP. In order to evaluate the contribution of the conserved AREs (ARE1/ ARE2 were examined together since they overlap), we mutated the sites within the full-length 3 ′ UTR and inserted them downstream of the luciferase reporter construct ( Fig. 4C and D). Co-transfection of the full-length 3 ′ UTR containing mutations at each conserved AREs (ARE1/ARE2 with ARE4) together with an overexpression KSRP vector (CMV-KSRP) completely abolished (P . 0.05) the decreased expression of luciferase upon increased levels of KSRP (Fig. 4E) . However, individual mutations of conserved AREs (ARE1/ARE2 versus ARE4) did not prevent the reduction in luciferase mRNA levels seen with overexpression of KSRP (Fig. 4E ). Additional RNA immunoprecipitation (RIP) experiments showed that mutations of the conserved AREs decreased significantly (P , 0.001) the binding of KSRP to the utrophin A full length 3 ′ UTR, as measured by the abundance of reporter mRNAs in the immunoprecipitates, with simultaneous mutations causing a greater reduction in binding than individual ones (Fig. 4F) . Collectively, these results demonstrate that KSRP directly controls utrophin A mRNA stability, and that this effect is dependent upon conserved AREs.
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KSRP interacts specifically with utrophin A mRNA
Since the above experiments indicated that KSRP-mediated utrophin A destabilization is dependent upon its AREs, we further examined the pattern of interaction between these AREs and KSRP. In order to evaluate the binding of KSRP to these regions, we performed RNA electrophoretic mobility shift assays (REMSAs) using different subfragments of the utrophin 3 ′ UTR containing conserved AREs. Radiolabeled ARE probes were incubated with a purified GST -KSRP fusion protein. As shown in Figure 5A , ARE1/2 and ARE4 of the mouse utrophin A 3 ′ UTR formed complexes with GST -KSRP and were readily detectable by autoradiography (see also Fig. 5B and C). This binding activity was much reduced using a probe encompassing a non-conserved (nc) ARE, nor was it observed with incubation of GST protein alone (Fig. 5A ). The specificity of the interaction between KSRP and different 3 ′ UTR subfragments that included ARE1/2 or ARE4 was further observed by mutating the ARE to GC-rich elements, or by adding increasing concentrations of cold probes ( Fig. 5B and C). These results demonstrate that KSRP specifically and directly binds conserved AREs contained within the utrophin A 3 ′ UTR. ′ UTR or mutated versions (see Fig. 4C ). Samples were immunoprecipitated with either IgG as control, or with an antibody against KSRP. qRT-PCR analyses revealed a decreased amount of luciferase mRNAs interacting with KSRP in mutated constructs. Values are expressed as means + SE (n ¼ 3 per group).
* P , 0.05; * * P , 0.01; * * * P , 0.001; relative to the corresponding control. $$$, P , 0.0001; relative 3 ′ UTR-WT immunoprecipitated with KSRP antibody. ( 
Activation of p38 alters the interaction between KSRP and utrophin A mRNA
To demonstrate whether activation of p38 signaling regulates the pattern of interaction between KSRP and utrophin A mRNA, we performed additional RNA immunoprecipitation experiments with C2C12 cells transfected with MKK6-EE. Twenty-four hours following transfection, cells were cross-linked and protein -RNA complexes were immunoprecipitated with either an anti-KSRP antibody or IgG as a control. Total RNA extracted from both input and immunoprecipitated samples were analyzed by a real-time qRT-PCR. In these assays, we observed that anti-KSRP antibody specifically immunoprecipitated utrophin A mRNAs but did not interact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs (Fig. 5D) , importantly confirming that endogenous KSRP is capable of interacting with utrophin A mRNA in muscle cells and that it is thus part of the utrophin A mRNP complex. In agreement with our functional data, this interaction was significantly reduced (P , 0.05) in C2C12 cells transfected with the MKK6-EE constitutively active mutant causing activation of p38 signaling and phosphorylation of KSRP (Fig. 5E ) despite the increased expression of utrophin A mRNA seen under these conditions (Fig. 1) . These results show therefore that the extent of interaction between KSRP and utrophin A transcript is markedly influenced by activation of p38 signaling which in turn modulates the destabilization potential of KSRP toward this target mRNA.
Activation of p38 reduces the functional availability of KSRP via two parallel mechanisms
Next, we investigated the mechanisms involved in the regulation of KSRP binding to the utrophin A mRNA by p38 activation. In this context, previous work showed that phosphorylation of KSRP by Akt causes its sequestration by 14-3-3, thereby explaining its reduced ability to interact with target transcripts and promote their destabilization (51, 55) . To examine whether the activation of p38 alters the pattern of interaction between KSRP and 14-3-3, we overexpressed MKK6-EE and immunoprecipitated KSRP from the cells. Western blotting of immunoprecipitates showed an increased KSRP/14-3-3 interaction upon p38 activation ( Fig. 6A and B ). To further demonstrate the role of p38 signaling in this interaction, we overexpressed MKK6-EE in C2C12 cells and treated the cells with 50 mM SB203580 to inhibit p38. Under these conditions, we observed in co-immunoprecipitation experiments, a reduced interaction between 14-3-3 and KSRP ( Fig. 6C and D) . Our results suggest therefore that sequestration of KSRP by 14-3-3 may ultimately contribute to the enhanced stability of utrophin A mRNA following p38 activation by reducing its functional availability for conserved AREs.
In these experiments, we also measured expression of KSRP upon p38 activation. Surprisingly, KSRP protein levels significantly decreased (P , 0.01) in response to activation of p38 signaling via overexpression of MKK6-EE (Fig. 6E -H ). Similar to KSRP protein, levels of KSRP transcripts were also decreased (P , 0.01) in cells with stimulated p38 signaling (Fig. 6F) . In reverse experiments, inhibition of p38 signaling for 24 h using a specific inhibitor (SB203580), induced an increase in KSRP protein (P , 0.001) and mRNA (P , 0.05; Fig. 6E -H) . The latter increase in the levels of KSRP was mirrored by a downregulation of utrophin A expression (Fig. 6E) . Additionally, chemical inhibition of p38 signaling in myotubes caused a decrease and increase in the levels of utrophin A and KSRP, respectively (data not shown). Taken together, these data demonstrate that activation of p38 interferes with the ability of KSRP to destabilize ARE-containing mRNAs via: (i) enhanced sequestration of phosphorylated KSRP by 14-3-3 and (ii) reduced expression of KSRP. Such combined effects of p38 activation on KSRP result in a dramatic reduction in the functional availability of KSRP, thereby leading to powerful modulations in the levels of utrophin A transcript and protein.
KSRP-mediated upregulation of utrophin A occurs in skeletal muscle in vivo
In separate experiments, we examined whether the destabilizing effects of KSRP on utrophin A mRNA also occurred in vivo. This appeared particularly important especially if the ultimate goal is to eventually manipulate KSRP activity in attempts to promote utrophin A expression in dystrophic muscle. For this, we used 6-week-old C57BJ and mdx mice. The mdx mouse is a widely accepted DMD model caused by a point mutation in the dystrophin gene that introduces a premature stop codon (56) . Tibialis anterior (TA) muscles from wild-type and mdx mice were electroporated with a short-hairpin RNA targeting KSRP mRNA or with the corresponding control vector. In our work, we chose electrotransfer of constructs into TA muscles as we (57) and others (58, 59) do routinely for such experiments. This approach allows for the rapid and reliable transfer of various constructs into skeletal muscle with high transduction efficiency. A major advantage of using the TA muscle for this type of work is its accessibility on the surface of the lower limb. Additionally, one of the TA muscles is used as an experimental side while the contralateral TA is used for electrotransfer of control vectors.
Seven days after injection/electroporation, KSRP mRNA and protein levels were strongly decreased (P , 0.05) in response to the KSRP knockdown in TA muscles (Fig. 7A-C) . As observed with cultured myogenic cells, we also detected in vivo, an increase in the levels of utrophin A mRNA (P , 0.01) and protein (P , 0.05) in TA muscles with reduced expression of KSRP (Fig. 7A, D and E) . This effect was not only observed in wild-type mice but also, and importantly, in mdx animals. In fact, the impact of manipulating the levels of KSRP on utrophin A expression was nearly identical in both mouse strains.
In co-injection experiments, we also noted that knocking down KSRP in TA muscles resulted in a 60% increase (P , 0.05) in the activity of the luciferase reporter containing the utrophin 3 ′ UTR (Fig. 7F) . Finally, RIP assays using TA muscle protein extracts revealed that KSRP interacts with utrophin A mRNA in vivo (Fig. 7G) . Together, these data show that KSRP interacts with endogenous utrophin A mRNA and that downregulation of KSRP enhances utrophin A transcript and protein expression in both wild-type and mdx skeletal muscle.
Pharmacological activation of p38 signaling increases utrophin A expression
The above results constitute proof-of-principle demonstrating that manipulation of KSRP's functional availability can induce significant changes in utrophin A expression. On this basis, we additionally determined in a last series of experiments, the impact of pharmacologically activating p38 signaling on utrophin A expression and localization in cultured myogenic cells as well as in mdx mice. Initially, we treated C2C12 cells with heparin since it is a known activator of p38 signaling pathway (60, 61) . Incubation of C2C12 cells with heparin induced phosphorylation of p38 (P , 0.01) while the total levels of p38 remained unchanged (Fig. 8A and B) . Similar to what we observed with overexpression of MKK6-EE in C2C12 cells,
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activation of p38 signaling by heparin induced a significant (P , 0.01) decrease and increase in KSRP and utrophin A (P , 0.001), respectively ( Fig. 8C and D) . In these experiments, we also noted that the levels of endogenous utrophin A mRNA were higher (P , 0.001) in C2C12 cells treated with heparin (Fig. 8E) . Furthermore, luciferase activity was increased (P , 0.001) in C2C12 cells transfected with the reporter construct containing the utrophin A full-length 3 ′ UTR and treated with heparin compared with saline (Fig. 8F) . Finally, we determined the half-life of utrophin A mRNA in cells treated with heparin versus saline. As shown in Figure 8G , the half-life of utrophin A mRNA was significantly increased (P , 0.01) in cells incubated with heparin (t 1/2 ¼ 13.85 + 0.53 h) compared with cells treated with saline (t 1/2 ¼ 7.31 + 1.35 h). Together, these data demonstrate that pharmacological activation of p38 signaling with heparin leads to enhanced expression of utrophin A through changes in the stability of existing utrophin A mRNAs.
In complementary studies, we treated 6-week-old mdx mice with heparin for 10 days and examined expression of utrophin A in diaphragm muscles. For these studies, we focused on the diaphragm muscle since it is well known that this muscle is most severely affected in mdx mice and better reflects the human pathology (62) . In agreement with our data presented above, treatment of mdx mice with heparin caused an increase (P , 0.05) in p38 phosphorylation and a decrease (P , 0.05) in the abundance of KSRP (Fig. 9A) . These changes were accompanied by a significant increase (P , 0.05) in utrophin A expression (Fig. 9B) . Importantly, immunofluorescence experiments further revealed an increase in utrophin A at the sarcolemma of muscles from treated versus untreated mdx mice (Fig. 9C) .
DISCUSSION
In this work, we show that activation of p38 signaling regulates expression of utrophin A transcripts and protein in skeletal muscle cells. In these experiments, we largely excluded the involvement of transcriptional mechanisms thereby suggesting that the increase in utrophin A expression following p38 activation is exclusively dependent on post-transcriptional events. In this context, we have identified KSRP as a key factor mediating the stability of pre-synthesized utrophin A mRNAs that acts through conserved AREs located in the utrophin A 3 ′ UTR. We have further shown that activation of p38 reduces the functional availability of KSRP for utrophin A transcripts leading to important increases in utrophin A mRNA and protein. Importantly, we demonstrated that these mechanisms operate not only in myogenic cells in culture but that they also occur in skeletal muscle in vivo of both wild-type and mdx mice. Finally, we show that heparin-induced activation of p38 signaling in mdx mouse muscles causes an increase in utrophin A expression. Taken together, these findings highlight the central role of p38 in mediating the post-transcriptional regulation of utrophin A in skeletal muscle cells, thereby raising the interesting Figure 9 . Heparin-induced activation of p38 signaling increases utrophin A expression in mdx muscles. Six-week-old mdx mice were treated daily with heparin and 10 days later, diaphragm muscles were excised and analyzed by western blots and immunofluorescence. (A) Western blots and their quantification, respectively, for p38 Thr180/Tyr182, KSRP and total p38 (P38-T) with b-actin as a control. Note the increase in the ratio of phosphorylated to total p38 (p38-P/T) in muscles treated with heparin together with a decrease in KSRP. (B) Representative western blots of utrophin A expression in diaphragm muscles of heparin-treated mdx mice. Note the significant increase in utrophin A levels. (C) Are representative examples of diaphragm muscle cross-sections stained with an antibody against utrophin A. Note the increase in utrophin A at the sarcolemma of heparin-treated mdx mice (n ¼ 4) compared with vehicle-treated mdx animals (n ¼ 3). Values are expressed as means + SE ( * P , 0.05 relative to the corresponding control; Fig. 9A and B: unpaired t-tests).
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possibility that pharmacological activation of p38 signaling can be of functional benefit to DMD muscle by stimulating utrophin A expression.
KSRP regulates the stability of utrophin A mRNA
Although much of the previous work dealing with the regulation of utrophin A in skeletal muscle has focused on transcriptional events, several laboratories including ours have shown over the last several years that expression of utrophin A is also controlled by post-transcriptional and translational regulatory mechanisms (28) (29) (30) (31) (32) (33) . Of particular relevance, our earlier work demonstrated that the utrophin A full-length 3 ′ UTR regulates the abundance of reporter mRNAs in muscle cells and that it contains several putative AREs (28, 29) . It is well documented that AREs consist of important regulatory domains located in the 3 ′ UTR of several target mRNAs that are subject to rapid changes in expression through post-transcriptional events operating at the level of transcript stability. To mediate their effects on the longevity of mRNAs, AREs require interactions with AUBPs (34, 35, 63) . Until now however, the identity of AUBPs leading to changes in the stability of utrophin A transcripts was completely unknown. Here, using several complementary approaches, we show that KSRP binds preferentially to conserved AREs located within the utrophin A 3 ′ UTR and that it functionally regulates the expression of utrophin A mRNA and protein in cultured myogenic cells as well as in muscle from wild-type and mdx mice.
KSRP is a multi-KH domain single-stranded DNA-and RNAbinding protein implicated in RNA metabolism (64, 65) . It is also known as FUSE-binding protein 2 (FBP2), and was originally identified as a transcriptional regulator of c-myc (66) . It was soon after reported as an alternative splicing factor for a neurospecific exon in the c-src pre-mRNA (67) . KSRP is the human homolog of chick zipcode binding protein 2 (ZBP2) and rat MARTA1, which are involved in neuronal localization of b-actin and microtubule-associated protein 2 (MAP2) mRNAs, respectively (68, 69) . KSRP is essentially a nuclear protein that structurally contains a nuclear localization signal (NLS), a proline-to-glycine-rich domain at its N-terminal, and a tyrosine-rich motif at its C-terminal (66) . The KH motifs are necessary to recognize ARE-containing mRNAs. Over the years, KSRP has clearly emerged as a key regulator of mRNA stability based on its ability to bind specific subsets of AREcontaining mRNAs and promote their rapid decay by recruiting the degradation machinery (52, (70) (71) (72) . Thus, KSRP is now well recognized as an important destabilizing factor in the control of mRNA stability.
To date, most studies that have focused on elucidating the role of KSRP in mRNA stability have been conducted in the immune system in which mRNA targets have been identified but with little to no knowledge of the physiological significance of these interactions (72 -74) . Moreover, and to our knowledge, there are only a handful of studies that examined its putative role in the neuromuscular system. Interestingly, some of these studies have examined developmental steps with somewhat contradictory findings. Whereas KSRP was shown to promote neurite extension in vitro (75), others have recently observed that KSRP negatively regulates muscle development by promoting decay of crucial myogenic mRNAs including myogenin, and p21 (50, 76) . Thus, our observations that KSRP interacts with utrophin A mRNA adds critically needed information as to its physiological function while also specifically contributing to a better understanding of post-transcriptional events in the neuromuscular system.
P38 signaling controls utrophin A expression via post-transcriptional events
It is well established that p38 signaling plays key roles in a variety of cells by regulating multiple processes including cell growth, cell cycle arrest and apoptosis (77) (78) (79) . In skeletal muscle, activation of p38 is known to modulate expression of several muscle genes under distinct experimental conditions through either transcriptional or post-transcriptional mechanisms (50, 80, 81) . Here, we observed that activation of p38 causes important increases in the expression of utrophin A mRNA and protein, independently of promoter activation thereby highlighting the importance of post-transcriptional events. These increases in utrophin A expression are also seen in mdx mice treated with heparin which activates p38, thereby demonstrating that manipulation of this pathway can lead to important beneficial changes in dystrophic muscle. In this context, a number of studies have previously shown that p38 signaling can regulate the stability of pre-existing transcripts in the immune system by acting via AREs and AUBPs (82 -85) . Using multiple approaches, we show in the present work that activation of p38 signaling leads to phosphorylation of KSRP which, in turn, reduces its binding to utrophin A transcripts, thereby increasing their stability and hence, their availability for translation.
The mechanisms by which p38 activation decreases the ability of KSRP to mediate its destabilizing impact on target transcripts are beginning to emerge. Clearly, direct phosphorylation of KSRP by this signaling pathway is necessary in order to alter the pattern of interactions between KSRP and target transcripts (50) . In addition, it appears that phosphorylation of KSRP mediates its interaction with 14-3-3 protein (55), which is known to bind a variety of phosphorylated proteins. Therefore, such an increased interaction between KSRP and 14-3-3 likely sequesters KSRP, thereby reducing its availability for AREs located in target transcripts causing in turn, an increase in their stability. Such an inhibitory model is further supported by our results showing that the constitutively active MKK6-EE kinase abrogates KSRP-mediated destabilization of utrophin A mRNA while concomitantly stimulating the binding of KSRP to 14-3-3 protein and out-competing it for AREs. Our results underscore therefore the important function of 14-3-3 in the posttranscriptional regulation of ARE-containing mRNAs in skeletal muscle.
Another novel finding shown here is the ability of p38 activation to decrease endogenous expression of KSRP at both protein and mRNA levels. Although the exact events involved in this down-regulation are currently unknown, they may involve pretranslational events linked to changes in KSRP mRNA levels as we observed in the present work, and/or the proteosomal degradation machinery upon p38 activation (86, 87) . Nonetheless, combined with our findings showing an increased interaction between KSRP and 14-3-3 upon p38-mediated phosphorylation, these results indicate that p38 is a powerful inhibitory modulator
of the functional availability of KSRP acting at two distinct levels. Such inhibition of KSRP function induces marked increases in the stability of ARE-containing transcripts as shown here for utrophin A mRNA.
Additional signaling pathways controlling post-transcriptional events
In addition to being phosphorylated at threonine 692 via the p38 MAP Kinase pathway (50), the activity of KSRP is also regulated by phosphorylation at serine 193, which is located within the first KH motif. The latter phosphorylation event is mediated via a distinct pathway involving in this case PI3K/Akt signaling (51). Akt-mediated phosphorylation of KSRP promotes its interaction with 14-3-3 protein, and similarly impairs its ability to promote degradation of mRNA targets (50, 51, 64) . In this context, previous reports indicate that activation of Akt signaling in mdx muscle is beneficial, since it promotes regeneration and enhances expression of utrophin A (88, 89) . Based on the foregoing discussion and the results presented here, it is temping to speculate that the positive impact of Akt activation on mdx muscle is linked, at least in part, to phosphorylation of KSRP and alterations in its ability to destabilize utrophin A transcripts. Recent work from our laboratory has shown that utrophin A expression is subject to transcriptional events involving calcineurin/NFAT (25,90) through calcium signaling (91) . More specifically, specific calcium signals activate calcineurin which, in turn, dephosphorylates NFAT leading to the nuclear translocation of this transcription factor and stimulation of a transcriptional program causing upregulation of several genes including utrophin A (90) . In additional work, we have shown that calcineurin signaling appears to also play an important and parallel role in controlling the stability of utrophin A mRNA (28) . Of relevance in this latter case, is the fact that treatment with cyclosporine A, a potent immunosuppressive inhibitor of the phosphatase activity of calcineurin, regulates IL-3 expression by causing destabilization of its mRNA (92) . Moreover, Nechama et al. have reported that the post-transcriptional regulation of parathyroid hormone (PTH) mRNA is regulated by calcium, and that in parathyroid glands of low calcium fed rats, KSRP binds less PTH mRNA correlating with an increase in PTH mRNA stability (53) . In other work, calcineurin signaling was also shown to modulate post-translationally the binding activity of AUF1, another AUBP, to PTH mRNA (93) . It thus seems likely that calcium/calcineurin signaling can also modulate the binding capacity of KSRP to target transcripts by determining the extent of its phosphorylation status in skeletal muscle. Alternatively, and in light of recent work showing that calcium/calmodulin signaling activates the p38 MAPK pathway (94) , it also appears to be possible that calcium/calmodulin signaling enhances the stability of transcripts through direct activation of p38 signaling which, as shown here, affects KSRP. Further studies seem warranted to assess and partition the impact of these additional signaling pathways on the post-transcriptional regulation of utrophin A mRNA, while also determining their impact on the phosphorylation status of KSRP. Nonetheless, it seems reasonable to argue that ultimately the fine balance between phosphorylated versus dephosphorylated AUBP could profoundly and simultaneously influence expression of several target transcripts in skeletal muscle.
Conclusion and perspective
The present study identifies KSRP as an important negative regulator in the post-transcriptional control of utrophin A in skeletal muscle while also revealing that p38-mediated phosphorylation of KSRP impairs this mRNA decay mechanism, thus promoting utrophin A expression. Importantly, we show in mdx mice that knocking down KSRP or activation of p38 via heparin cause a 70-250% increase in utrophin A mRNA and protein in dystrophic skeletal muscle. Such increases in utrophin A expression are significant, especially since previous studies have clearly shown that even modest augmentation in utrophin A in mdx muscle results in important functional benefits (21, (95) (96) (97) (98) . Thus, our findings pave the way for developing novel therapeutic strategies based on decreasing the functional availability of KSRP in dystrophic muscle. In this context, p38 activation appears to be pivotal as it would simultaneously cause an increase in KSRP phosphorylation leading to its sequestration by 14-3-3, and a decrease in its expression as shown here. Therefore, clinical strategies aimed at activating p38 signaling in dystrophic muscle may prove extremely beneficial for DMD particularly since this pathway is known to be deactivated in dystrophic muscle (99, 100) . Additionally, p38 activation in dystrophic muscle may also enhance muscle regeneration (80, 101, 102) as shown in fact using heparin (103 -105) . Such a pharmacological approach could lead to important increases in utrophin A expression, thereby compensating for the lack of dystrophin in DMD muscle fibers. The fact that some of these p38 activators are already in clinical use could accelerate the development and implementation of novel effective therapies for DMD patients.
MATERIALS AND METHODS
Cell culture, plasmids and transfection
Mouse C2C12 cells (American Type Culture Collection, Manassas, VA, USA) were plated on six-well culture dishes coated with Matrigel (BD Biosciences, Bedford, MA, USA) in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Wisent, St-Bruno, QC, Canada), L-glutamine and penicillin/streptomycin and grown in a humidified chamber at 378C with 5% CO 2 . Mouse Neuro-2a (N2A) neuroblastoma cells, terminally differentiated (American Type Culture Collection, Manassas, VA, USA), were maintained in DMEM supplemented with sodium pyruvate, penicillin, streptomycin and fetal bovine serum.
Transient transfections were performed using Lipofectamine (Invitrogen) according to the manufacturer's instructions. Cells at 50-60% confluency were incubated with the Lipofectamine/DNA mix for 4 h and harvested 12-24 h after transfection for analysis. MKK6-EE and MKK6-AA plasmids were kindly provided by Dr Alex MacKenzie (Apoptosis Research Center, Children's Hospital of Eastern Ontario Research Institute). The 1.3 kb human utrophin A promoter was subcloned upstream of the Firefly luciferase gene in pGL3 basic vector (45) . The pGL3-myogenin and pGL3-MyoD-PRR promoter Firefly luciferase constructs (48) ′ UTR were generated using the Quick Change Lightning site-directed mutagenesis kit (Stratagene) and corresponded to T to G/C substitutions. Mutations were verified by DNA sequencing. Cells were co-transfected with 50 ng of a Renilla luciferase reporter (phRGtk-luc) to control for transfection efficiency. For sh-RNA transfections, C2C12 cells ( 40% confluence) were plated in six-well plates and transfected the following day in serum-free DMEM with KSRP-pRS-Sh-RNA (2 mg) or pRS-Sh-RNA control Sh-RNA (2 mg), using Lipofectamine 2000 transfection reagent for 48 h.
Mouse KSRP cDNA with a Myc tag was inserted into the EcoRI and XhoI sites of a pCMV-Myc vector. For overexpression studies, this construct or its empty control vector was transfected into N2a cells as described above.
Animals and electrotransfer of plasmid DNA
Six-week-old male C57BJ and mdx mice were maintained in the Animal Care and Veterinary Service of the University of Ottawa, under a constant 12 h light -dark cycle with food and water ad libitum. The experimental protocols were all approved by the University of Ottawa Institutional Animal Care and User Committee. Electrotransfer of KSRP-pRS-Sh-RNA into TA muscles was performed as described elsewhere (57) while the animals were under anesthesia. The contralateral TA muscle of each mouse was injected with pRS-Sh-RNA as a control. Seven days after electroporation, mice were euthanized and muscles were frozen in liquid nitrogen. All muscle samples were stored at 2808C for subsequent analyses.
Heparin treatment
Mouse C2C12 cells were plated on six-well culture dishes, and treated with heparin (LEO Pharma) at different concentrations (1.25, 2.5, 3.75, 5 UI/ml) or with saline for 6 -24 h. For in vivo experiments, 6-week-old mdx mice received daily subcutaneously injections with heparin at a concentration of 500 UI/kg in a volume of 50 ml of sterile saline (60) . As a control, agematched mdx mice were injected with a sterile saline solution. After 10 days, the animals were euthanized and diaphragm muscles were dissected and flash frozen in liquid nitrogen or embedded in OCT compound and frozen in melting isopentane cooled by liquid nitrogen.
Protein extraction and immunoblot analyses
Proteins were extracted from powdered muscles by homogenization at 48C in RIPA buffer (Sigma-Aldrich). Homogenates were centrifuged at 12 000g for 12 min at 48C, and supernatants were collected and stored in aliquots at 2808C. Protein concentration was measured using the Bio-Rad DC Protein Assay kit. For western blotting, 50 mg of proteins were subjected to SDS -PAGE and transferred to nitrocellulose membranes. Gel loading was systematically checked by Coomassie Blue and Ponceau S staining. Blots were incubated overnight at 48C with primary antibodies against utrophin (Novocastra NCL-DRP2, Newcastle upon Tyne, UK), KSRP (Bethyl Laboratories), GAPDH (Advanced Immunochemical, Long Beach, CA), b-actin (Santa Cruz Biotechnology) as well as p38 MAPK, p38b MAPK, phospho-MKK3 (Ser189)/MKK6 (Ser207), phospho-p38 MAPK (Thr180/Tyr182) and 14-3-3 antibodies (all from Cell Signalling Technology). Murine hybridomas producing a mouse monoclonal antibody to KSRP (Ab5) were kindly provided by Dr Douglas L Black (Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, USA) (75) .
Incubation with the corresponding horseradish peroxidaseconjugated rabbit anti-mouse antibodies (KPL, Kirkegaard & Perry laboratories), rabbit anti-goat antibodies (Jackson ImmunoResearch) or horseradish peroxidase-conjugated-protein A (ZYMED) was performed for chemiluminescent detection of proteins (ECL; PerkinElmer). The films were scanned and quantified using NIH Image version 1.63.
KSRP immunoprecipitation
C2C12 cells were lysed with RIPA buffer and incubated with a rabbit polyclonal KSRP antibody overnight at 48C. Complexes were immunoprecipitated using protein G Sepharose (Sigma Aldrich, St Louis, MO) for 3 h at 48C and then washed with RIPA buffer supplemented with protease and phosphatase inhibitors, and analyzed by resolving 10% SDS -PAGE and immunoblotting with 14-3-3 and KSRP antibodies.
RNA extraction and RT-PCR
Total RNA was extracted from muscle and C2C12 cells using TRIzol reagent (Invitrogen) as recommended by the manufacturer. TRIzol extracted RNA was treated for 1 h with DNAse I (Invitrogen) to eliminate possible DNA contamination. Reverse transcription (RT) was carried out using an RT reaction mixture containing 5 mM MgCl 2 , 1× PCR buffer, 1 mM dNTP, 1 U/ml RNase inhibitor, 5 U/ml Moloney murine leukemia virus reverse transcriptase and 2.5 mM random hexamers (Applied Biosystems, CA, USA).
A real-time quantitative PCR was performed on an MX3005p real-time PCR system (Stratagene, La Jolla, CA, USA) using a QuantiTect SYBR Green PCR kit (QIAGEN, Valencia, CA, USA). For these experiments, amplification of the 18S ribosomal subunit, GAPDH, utrophin A and KSRP was performed in triplicate with the following primer sequences: utrophin, forward Muscle cross-sections (10 mm) were cut with a microtome at 2208C and stained with utrophin antibodies along with Alexa 488-conjugated a-bungarotoxin to label neuromuscular junctions (Jackson ImmunoResearch, West Grove, USA). Immunofluorescence experiments were performed simultaneously on diaphragm muscle samples from control and heparin-treated mdx mice, placed on the same slides. Quantification of the fluorescence intensity was performed using ImageJ (NIH).
Luciferase assays
C2C12 cell and TA muscle samples were homogenized (1:10 dilution, w/v) in reporter lysis buffer (Dual Luciferase Assay System, Promega, Madison, WI, USA), subsequently frozen in liquid nitrogen and thawed and re-frozen three times at 378C. The activity of Firefly and Renilla luciferase was determined using the Dual Luciferase Assay kit. To correct for variations in transfection/transduction efficiency, Firefly luciferase activity was normalized to Renilla luciferase activity.
RNA electrophoretic mobility shift assays (REMSA)
REMSA using specific regions of the utrophin A 3 ′ UTR and GST-KSRP was performed as previously described (32) . KSRP from pCMV-Myc-KSRP was subcloned into pGEX-4T2 (Acc. No. U13854; GE Healthcare, Piscataway, NJ, USA) using its EcoRI and XhoI sites. GST, and GST-KSRP fusion constructs were subsequently overexpressed in Escherichia coli BL-21 competent cells (Stratagene) by induction with 0.1 mM isopropyl-B-D-thiogalactopyranoside (IPTG) at 378C for 3 h. After induction, cells were spun down and resuspended in 10 mL of 1× PBS supplemented with Complete TM Protease Inhibitor Cocktail Tablets (Roche, Laval, QC, Canada) and broken down by sonication (five pulses of 15 s at 12 watts). Cellular debris were centrifuged for 20 min at 10 000g and GST-KSRP from the supernatant was purified using glutathione-agarose beads (Sigma) and extensive washes with 1× PBS wash buffer. To facilitate collection for UV crosslinking assays, fusion proteins were not eluted from the GST beads and were instead resuspended as 50% V/V in 1× PBS supplemented with Complete TM tablets.
RNA immunoprecipitation (RIP)
C2C12 cells were cross-linked with 1% formaldehyde in PBS for 10 min at room temperature. The reaction was stopped with a wash in ice-cold PBS. Equal amounts of whole cell extracts were immunoprecipitated with a Protein A agarose-bound rabbit anti-KSRP antibody (Bethyl Laboratories, USA) beads (Sigma) or rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) as control. The beads were washed with modified RIPA buffer supplemented with protease and phosphatase inhibitors (Roche) and heated to 708C for 1 h to reverse cross-linking. RNA was extracted using Tripure Reagent (Roche). A real-time quantitative RT -PCR was performed as described above. RIP assays using TA muscles were performed as described (53) .
Statistics
Various statistical tests including paired and unpaired t-tests, as well as one-way analysis of variance followed by Bonferroni's tests, were used to determine whether specific group mean differences were significant. Each test that was performed is specified in the figure legends. The minimum a-level of significance was set at 0.05. Data are presented as means + SEM throughout.
